DiaMedica Therapeutics (NASDAQ:DMAC - Free Report) had its target price raised by Lake Street Capital from $11.00 to $14.00 in a report released on Friday morning,Benzinga reports. Lake Street Capital currently has a buy rating on the stock.
DMAC has been the topic of several other research reports. Craig Hallum boosted their price target on shares of DiaMedica Therapeutics from $8.00 to $11.00 and gave the company a "buy" rating in a research report on Friday. HC Wainwright boosted their price target on shares of DiaMedica Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a research report on Friday.
Check Out Our Latest Report on DiaMedica Therapeutics
DiaMedica Therapeutics Price Performance
Shares of NASDAQ DMAC traded up $0.48 during mid-day trading on Friday, reaching $4.66. 473,397 shares of the company's stock traded hands, compared to its average volume of 112,747. The stock has a market cap of $199.78 million, a P/E ratio of -7.30 and a beta of 1.17. The business has a 50-day simple moving average of $3.93 and a 200 day simple moving average of $4.68. DiaMedica Therapeutics has a 1-year low of $3.19 and a 1-year high of $6.82.
DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.18) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.18). During the same period in the previous year, the company posted ($0.14) earnings per share. Equities research analysts anticipate that DiaMedica Therapeutics will post -0.59 earnings per share for the current fiscal year.
Hedge Funds Weigh In On DiaMedica Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of DMAC. Cornerstone Wealth Management LLC bought a new position in DiaMedica Therapeutics during the 1st quarter worth approximately $62,000. Balyasny Asset Management L.P. bought a new position in DiaMedica Therapeutics during the 4th quarter worth approximately $79,000. Raymond James Financial Inc. bought a new position in DiaMedica Therapeutics during the 4th quarter worth approximately $83,000. Bank of Montreal Can bought a new position in DiaMedica Therapeutics during the 4th quarter worth approximately $84,000. Finally, World Investment Advisors lifted its holdings in DiaMedica Therapeutics by 17.0% in the 1st quarter. World Investment Advisors now owns 25,650 shares of the company's stock worth $97,000 after buying an additional 3,735 shares during the period. 10.12% of the stock is currently owned by institutional investors.
About DiaMedica Therapeutics
(
Get Free Report)
DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.
Featured Articles
Before you consider DiaMedica Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DiaMedica Therapeutics wasn't on the list.
While DiaMedica Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
